|
STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma. |
| |
|
Honoraria - Nanobiotix; PharmaMar |
Research Funding - Lilly; PharmaMar |
Travel, Accommodations, Expenses - PharmaMar |
| |
|
Honoraria - Lilly; Novartis; Pfizer; PharmaMar |
Consulting or Advisory Role - Bayer; Lilly; Nanobiotix; Novartis; Pfizer; PharmaMar |
Research Funding - PharmaMar (Inst) |
Travel, Accommodations, Expenses - Nanobiotix; PharmaMar |
| |
|
Consulting or Advisory Role - Amgen; AstraZeneca; Lilly; Nanobiotix |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche |
Consulting or Advisory Role - Amgen; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre |
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Pfizer |
Travel, Accommodations, Expenses - Orphan Europe |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Patents, Royalties, Other Intellectual Property - Amgen, Boehringer-Ingelheim, Pfizer, Novartis, Pharmamar, Daiichi, Five Prime (Inst) |
Other Relationship - Daiichi Sankyo |
| |
|
Honoraria - Nanobiotix; PharmaMar |
Consulting or Advisory Role - Nanobiotix |
Research Funding - GlaxoSmithKline (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Nanobiotix; Nanobiotix |